Bevacizumab combined with either of 2 chemotherapy backbones improved overall survival by 3.7 months versus chemotherapy alone in patients with advanced cervical cancer, according to data from the phase III GOG 240 study.
http://www.ajmc.com/publications/evidence-based-oncology/2013/2013-1-Vol19-sp6/Bevacizumab-Aids-Survival-in-Cervical-Cancer
http://www.ajmc.com/publications/evidence-based-oncology/2013/2013-1-Vol19-sp6/Bevacizumab-Aids-Survival-in-Cervical-Cancer
No comments:
Post a Comment